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analysis was from public documents, related audit reports, literature review, ob-
servations from the meetings of the NHI Benefits Negotiation responsible for rec-
ommending new technologies for the NHIBS and interviews with the meeting
participators. RESULTS: The Taiwan process for updating the NHIBS lacks the ap-
peals and enforcement conditions, and only partially follows the relevance and
publicity conditions. Only the reasonableness and transparency steps of the trans-
disciplinary model are partially fulfilled, but the priority setting process does not
satisfy responsiveness and accountability. CONCLUSIONS: The fairness and legit-
imacy of the priority-setting decision mechanism have not been established. The
lack of personnel engaged in health technology assessment and the desire for early
adoption of new technologies are an obstacle to achieving these conditions. Com-
prehensive changes in the priority-setting process should be made in order to
increase its acceptability among the different stakeholders.
HC4
TAPPING INTO THE ASIAN PHARMACEUTICAL MARKET: GLOBAL FIRMS GO
LOCAL?
Wong GKW, Brooks-Rooney C, Hamerslag L, Wilson TJ, Costello S
Costello Medical Consulting Ltd., Cambridge, UK
OBJECTIVES: To review the numbers of Phase III/IV clinical trials conducted in the
four Asian countries with the highest health care spending (China, Japan, Korea
and India), and the share of trials sponsored by the 12 multinational companies
(MNCs) with the highest revenues and profits, over the past 10 years. METHODS:
Searches were performed on ClinicalTrials.gov to identify industry-sponsored
Phase III/IV studies added in 2002, 2006 and 2011. The proportion of trials con-
ducted in China, Japan, Korea and India, and the percentages of trials sponsored by
12 MNCs (Pfizer, Johnson & Johnson, Merck, Abbott Laboratories, Eli Lilly, Bristol-
Myers Squibb, Amgen, Gilead Sciences, Mylan, Allergan, Biogen Idec and Gen-
zyme), were analysed. RESULTS: The total proportion of industry-sponsored Phase
III/IV trials in China, Japan, Korea and India increased over the time period studied
(5%, 17% and 22% in 2002, 2006 and 2011, respectively). In 2002 and 2006, the top 12
MNCs sponsored approximately one third of the Phase III/IV trials in the four coun-
tries. This figure, however, dropped to about 20% in 2011. Eight Phase III/IV studies
in 2011 were co-funded by one western manufacturer and an Asian firm. Notably,
no Asian partners were identified in the collaborative Phase III/IV trials in 2002 or
2006. CONCLUSIONS: The period of 2002-2011 saw an increase in the total number
of Phase III/IV trials conducted in the four Asianmarkets. However, the dominance
of the top MNCs in these markets seemed to be weakened during this period. Our
results also suggest that establishing partnerships with local companies might be
a key strategy for entering these major health care markets.
PODIUM SESSION I:
RESEARCH ON METHODS STUDIES
ME1
COMPARISON OF THE MEASUREMENT PROPERTIES BETWEEN THE 5-LEVEL
EUROQOL GROUP’S 5-DIMENSION (EQ-5D-5L) QUESTIONNAIRE AND THE
FUNCTIONAL ASSESSMENT OF CANCER THERAPY – BREAST (FACT-B) IN ASIAN
BREAST CANCER PATIENTS
Cheung YB1, Lee CF2, Luo N3, Ng R4, Wong NS4, Yap YS4, Lo SK4, Chia J4, Yee A4, Krishna L4,
Wong CF1, Goh C4
1Duke - National University of Singapore Graduate Medical School, Singapore, Singapore, 2Singapore
Clinical Research Institute, Singapore, Singapore, 3National University of Singapore, Singapore,
Singapore, 4National Cancer Center, Singapore, Singapore
OBJECTIVES: To compare the measurement precision and related properties be-
tween a short and generic instrument, 5-level EuroQoL Group’s 5-dimension (EQ-
5D-5L) questionnaire, and a longer and disease-specific measure Functional As-
sessment of Cancer Therapy – Breast (FACT-B) questionnaire in assessing breast
cancer patients. METHODS: This is an observational study of 269 Singaporean
breast cancer patients. To compare discriminative ability cross-sectionally and
longitudinally, the effect sizes (in standard deviation) of the EQ-5D-5L and the
FACT-B in relation to various health indicators were estimated. Test-retest reliabil-
ity was examined using the intraclass correlation (ICC) for patients with no change
in self-assessed performance status or quality of life. For each non-inferiority as-
sessment, a 90% confidence interval of the difference (FACT-B minus EQ-5D-5L) in
effect size or ICC was estimated and compared with a pre-defined non-inferiority
margin of 0.2. RESULTS: In a cross-sectional setting, the differences in the effect
size favored EQ-5D-5L and the 90% confidence intervals totally fell within the zone
that indicated the non-inferiority of the EQ-5D-5L (e.g. oncologist-assessed perfor-
mance status: –0.26 to 0.04; patient-assessed performance status: –0.48 to –0.16;
current evidence of disease: –0.28 to 0.08). In a longitudinal setting, the FACT-B
showed larger effect sizes and ICCs than the EQ-5D-5L. The confidence intervals,
however, overlapped the non-inferiority margin, thus non-inferiority in these two
aspects could not be confirmed. CONCLUSIONS: The EQ-5D-5L was non-inferior to
the FACT-B in discriminating breast cancer patients with different health condi-
tions cross-sectionally. Its longitudinal measurement properties need further in-
vestigations. Depending on the specific research aims of studies, the EQ-5D-5Lmay
serve as a reasonable alternative or supplementary instrument to the FACT-B in
assessing breast cancer patients’ health outcomes.
ME2
VALIDATION OF THE KIDNEY DISEASE AND QUALITY OF LIFE QUESTIONNAIRE
(KDQOL-36) IN HAEMODIALYSIS PATIENTS IN SINGAPORE
Yang F1, Wang VW2, Joshi VD2, Luo N3
1Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore,
2Center for Health Services Research, Singapore Health Services, Singapore, Singapore, 3National
University of Singapore, Singapore, Singapore
OBJECTIVES: The Kidney Disease and Quality Of Life questionnaire (KDQOL-36) is a
shorter version of the Kidney Disease and Quality of Life-Short Form (KDQOL-SF), a
widely used health outcomes instrument for patients with chronic kidney dis-
eases. The aim of this study was to validate the KDQOL-36 in haemodialysis pa-
tients in Singapore. METHODS: Secondary KDQOL-SF (version 1.3) data collected
from a cross-sectional survey of haemodialysis patients attending the National
Kidney Foundation (NKF) dialysis centres from December 2006 to January 2007 in
Singapore was used. The KDQOL-SF items used to construct the KDQOL-36 scales
were analyzed to assess their psychometric properties. Internal consistency reli-
ability was assessed using Cronbach’s alpha. Criterion validity of the physical com-
ponent summary (PCS-12) and mental component summary (MCS-12) was as-
sessed by examining their correlation with the PCS-36 andMCS-36 calculated from
the KDQOL-SF. Item-to-scale correlation was examined and exploratory factor
analysis was performed to test the scaling assumptions of the KDQOL-36.
RESULTS: Totally 394 patients (male: 55.8%; mean age [SD]: 52.4 [11.7] years) com-
pleted the survey in English. Cronbach’s  value of the KDQOL-36 scales ranged
from 0.70 to 0.91. Correlation between the PCS-12 and PCS-36 was 0.75 and corre-
lation between MCS-12 and MCS-36 was 0.80. Correlation of items with their hy-
pothesized scales was higher than their correlation with other scales for all
KDQOL-36 items. Principle component factor analysis indicated a three-factor
structure for the generic items (variance accounted for: 63.8%) and a four-factor
structure for the disease-specific items (variance accounted for: 62.6%). The dis-
ease-specific scales and the PCS-12/MCS-12 were weakly to moderately correlated
(range of correlation: 0.28 to 0.41).CONCLUSIONS:TheKDQOL-36 appears a reliable
and valid measure of quality of life for haemodialysis patients in Singapore. More
research needs to be conducted to assess the construct validity of the instrument
using clinical data.
ME3
CENSOR ADJUSTED NET MONETARY BENEFIT OF ANTI-HCV THERAPY IN THE
VARIETY OF REAL-WORLD TREATMENT SETTING
Hsu CN1, Kauf T2
1Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, 2University of Florida,
Gainesville, FL, USA
OBJECTIVES: This study demonstrates how net benefit regression was used for
estimating censor adjusted cost-effectiveness of combination anti-HCV regimens
in an observational database study. METHODS: The Integrated Health Care Infor-
mation Services (IHCIS) National Managed Care Benchmark Database during Jan-
uary 1, 1997 to June 30, 2007, was used to identify study subjects with newly-
diagnosed HCV infection. First was to identify the primary effectiveness on time to
end-stage liver disease (ESLD) free survival and total direct cost during the follow-
up. Study perspective was the managed care organization with 2007 value of dol-
lars. Censored effectiveness and total cost of HCV care were adjusted with inverse
probability of weighting for the likelihood of being censored based on baseline
patient characteristics. The incremental net monetary benefit (INB) of antiviral
therapy (vs. no treatment) was estimated in the ordinary least square linear regres-
sion with adjustments for potential confounding. The INBs were tested with
White’s correction for heteroskedasticity. RESULTS: Patients at the time of HCV
diagnosed related cirrhosis, 48 weeks of initial combination antiviral regimens
(peg-interferon alpha and ribavirin) was cost-effective when the willingness-to-
pay value is $40,000 (INB, 4828, 95%, -14688-24345) but longer duration therapy
was not. Initial therapy appeared no difference in ESLD prevention for patients
with cirrhosis free, although the incidence of ESLD was low between treated and
no-treated patients. Cirrhosis presented strong impacts on treatment initiation.
Despite for cirrhosis and age, comorbid conditions had differential influence on
efficiency which were failed to take into account in prior modeling approach.
CONCLUSIONS: The propensity score adjusted net monetary benefit can be a valid
measure of cost-effectiveness in the practice setting with heterogeneous treat-
ment effects. Although prior modeling studies suggested that threshold value to
being cost-effectivewas lower in patientswithout cirrhosis, the results seemed not
hold after adjustments for the likelihood of starting treatment and unmeasured
bias.
ME4
USING DISCRETE CHOICE EXPERIMENTS TO VALUE HEALTH STATES FOR
ECONOMIC EVALUATION – THE SF-6D IN AUSTRALIA
Norman R1, Viney R2, Brazier J3, Burgess L1, Cronin P1, King M4, Ratcliffe J5, Street DJ1
1University of Technology, Sydney, Australia, 2University of Technology, Sydney, Sydney,
Australia, 3University of Sheffield, Sheffield, South Yorkshire, UK, 4University of Sydney, Sydney,
Australia, 5Flinders University, Adelaide, South Australia, Australia
OBJECTIVES: Conventionally, generic quality of life health states, defined within
multi-attribute utility instruments, have been valued using a standard gamble or
time trade-off. Preference elicitation tasks for both are complicated, limiting the
number of health states each respondent can value, and therefore that can be
valued overall. Additionally, the two techniques have been shown to introduce bias
into health state valuation due to issues of (for example) discounting of future
events or risk preference. The objective of this research is to test an alternative
method for eliciting preferences for generic health states, and to produce an algo-
rithm for use in Australian cost-utility analyses.METHODS:We designed a DCE to
obtain values for SF-6D health states, and implemented it in an Australia-repre-
sentative online panel (n1,017). A range of specifications were estimated using a
random-effects probit model. Utility weights were then derived such that full
health and death were valued at 1 and 0 respectively. RESULTS: The results reflect
the broadly monotonic design of the SF-6D, and combination of levels to remove
illogical orderings did not lead to a poorer model fit. The most important dimen-
sions in the SF-6D were identified as physical functioning, pain, mental health and
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vitality. Australian values differed from those reported elsewhere. CONCLUSIONS:
This research provides an Australian algorithm for cost-utility analyses using the
SF-6D. DCEs are a valuable alternative approach to the time trade-off or standard
gamble. The explicit consideration of design principles is a major strength of the
study reported here.Morework, however, is required to identify howDCEs can best




A NOVEL METHOD FOR CALCULATING PREVALENCE OF MULTIPLE SCLEROSIS
IN AUSTRALIA
Palmer AJ, Hitchens PL
Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia
OBJECTIVES: To determine the prevalence of Multiple Sclerosis (MS) in Australia in
2010 using a novel method based on Australia-wide prescription data for MS-spe-
cific disease modifying agents. The results obtained were validated against the
results of the Australian Bureau of Statistics (ABS) survey of disability, ageing and
carers (SDAC) of 27,600 households and 200 non-private dwellings conducted in
2009, and against MS Society registered client numbers. METHODS: We obtained
the total number of scripts for medications that are used exclusively for the treat-
ment of MS written in Australia for the period January-December 2010 from the
Australian Pharmaceutical Benefit Services (PBS). Numbers of scripts dispensed
were obtained by state for Betaferon, Avonex, Copaxone, Rebif 44, and Tysabri.
Additional data, not captured in the PBS prescription data, was supplied by Biogen
on the number of prescriptions for Tysabri issued in the same period under the
Special Access Service arrangement. The percentage of MS patients using these
medications (42-46%) was taken from state-specific surveys of MS Society clients.
To estimate the total number of persons with MSwe divided the annual number of
scripts dispensed by 12 and adjusted for penetration of MS immuno-modifiers by
state. Sensitivity analysis was performed. RESULTS: The prevalence of MS in Aus-
tralia in 2010 calculated using the prescription method was 21,283 people (95.5 per
100,000). This compared to 21,200 (95.2/100,000) obtained from the ABS-SDAC sur-
vey of 2009, and 19,889 (89.3/100,000) using MS Society client numbers. Prevalence
increased with increasing latitude. Results were sensitive to the percentage of
people with MS assumed to be treated with disease modifying agents.
CONCLUSIONS: Nation-wide prescription data for MS-specific disease modifying
agents is a novel method for calculating prevalence of MS that generates results
that are similar to other potentially more resource intensive methods for calculat-
ing MS prevalence.
CL2
USEFULNESS OF DAYS LOST DUE TO DISABILITY AS A NEW METHOD IN
MEASURING BURDEN OF ADVERSE DRUG REACTIONS
Thomas D1, Vijaya Raghavan C2, Padmanabha Reddy Y1, Kumar BM3
1RDT/RIPER, Anantapur, AP, India; 2PSG College of Pharmacy, Coimbatore, TN, India; 3JDT Islam
College of Pharmacy, Kozhikode-Kerala, India
OBJECTIVES: To find out the usefulness of Days Lost due to Disability (DLD) in
calculating the burden of adverse drug reactions due to diclofenac.METHODS: The
studywas conducted in 2010 for the cohort dispensedwith diclofenac tablets in one
pharmacy at South India. Those who were co-prescribed with other anti-inflam-
matory agents and having serious co-morbidity were excluded from the study. The
study subjects (18-65 years) were instructed to report any suspected side effects on
their next visit or through phone call. DLD is calculated similar to Years Lost Due to
Disability (YLD) by multiplying the occurrence of Adverse Drug Reactions (ADRs),
its duration and disability weight. DW was calculated in an analogue scale of 0-1
were 0 is perfect health. Naranjo Causality assessmentwas used to qualify ADRs on
it probability. RESULTS: In a total of 1000 prescription of 943 patients’ 34 types of
ADRs were identified with a total score of 561. The most occurring ADRs were on
gastrointestinal system (48%). Abdominal pain occurred for 107 times. There were
only 34 cases of peptic ulcers but it was themost disabling ADRwith a DLD of 0.078.
There were only few cases of acute renal failure (DLD 0.012) and Steven-Johnson
Syndrome (DLD 0.013); still they scored a significant DLD as the outcomewasmore
damaging. DLD can be calculated only in recovered patients. DLD is a useful indi-
cator of assessing the burden of ADRs managed in different health care settings
with varying resources. CONCLUSIONS:DLD could represent the burden of ADR on
health. It considers the occurrence, duration and reduction in health due to ADRs.
So DLD could be a useful tool in assessing the outcome of ADRs.
CL3
ANTICOAGULATION CONTROL OF A PHARMACIST MANAGED
ANTICOAGULATION CLINIC IN A NATIONAL REFERRAL CENTRE IN MALAYSIA
Thanimalai S1, Shafie AA1, Ahmad Hassali MA2, Sinnadurai J3
1Universiti Sains Malaysia, Penang, Malaysia; 2Discipline of Social And Administrative
Pharmacy, Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia; 3Hospital
Kuala Lumpur, Kuala Lumpur, Wilayah Persekut, Malaysia
OBJECTIVES: Limited evidence is available regarding pharmacist managed antico-
agulation clinic (PMAC) in the Southeast Asian region where there is marked dif-
ference in terms of care model, genetic composition and patient demographics.
This study aimed at comparing the anticoagulation clinic managed by the phar-
macist with physician advisory and the usual medical care provided in Kuala Lum-
pur Hospital (KLH) in terms of anticoagulation control and adverse outcomes.
METHODS: A 2302 bedded government tertiary referral hospital in Malaysia. A
6-month retrospective cohort study of the effectiveness of 2 models of anticoagu-
lation care, the pharmacistmanaged anticoagulation clinic (PMAC) and usualmed-
ical clinic (UMC) in KLH was conducted, where a random number generator was
used to recruit patients. The UMC patients received standard medical care where
they aremanaged by rotationalmedical officers in the Physicians’ Clinic. As for the
PMAC with physician advisory, the pharmacist will counsel and review the pa-
tients Internationalised Normalization Ratio (INR) at each clinic visit and also ad-
just the patients’ warfarin dose accordingly. Patients are referred to physicians if
immediate attention is required. The main therapeutic outcome is time in thera-
peutic range both actual and expanded TTR and thromboembolic and bleeding
complications. RESULTS: Each of the PMAC and usual medical care recruited 92
patients, which totals to 184 patients. The patient demographics in terms of age,
race and indication of treatment were comparable. At the end of the 6 months
follow-up, patients in the PMAC group had significantly higher actual-TTR (65.1%
vs. 48.3%; P0.05) compared to those in usualmedical care group. Rates of bleeding
incidenceswere 6.5 versus 21.7 events per 100 person-years for the PMAC andUMC
groups, respectively. CONCLUSIONS: PMAC provided a significantly better antico-
agulation care than usual medical care. The PMAC with physician advisory has
been successfully implemented in Kuala Lumpur Hospital.
CL4
DRUG SWITCHING EVENTS AMONG USERS OF NSAIDS WITH OR WITHOUT
GASTRO-PROTECTIVE DRUGS AS AN EARLY DETERMINANT OF
DISSATISFACTION FROM GASTROINTESTINAL ADVERSE EVENTS
Chen JJ, Huang YB, Wen YH, Chen SH, Yang YH
Kaohsiung Medical University, Kaohsiung, Taiwan
OBJECTIVES: To examine the drug switching events among non-steroidal anti-
inflammatory drugs (NSAIDs) users and co-medication with gastro-protective
drugs (GPDs) as an early determinant of dissatisfaction from gastrointestinal (GI)
adverse events. METHODS: The Taiwan Longitudinal Health Insurance Database
2000 during 1997 to 2008 was used to identify patients with newly diagnosis of RA
(ICD-9-CM: 714.0-714.3) or OA (715.0-715.9) in 1998-2007 to allow for one or more
follow-up year. For each patient, the intervals were identified by any gaps of 30 or
more days between drug dispensing coverage. Intervals were classified into 3 cat-
egories: traditional NSAID (tNSIAD), preferential (pC2SI: meloxicam, etodolac,
nabumetone and nimesulide) or specific COX-2 selective inhibitor (COXIB: cele-
coxib, rofecoxib and etoricoxib). For each patient-interval, the event of switching
from one of the 3 categories to another was considered as the dissatisfaction with
early GI adverse events. Intervals with less than 60 days of NSAID dispensing were
excluded. Consideringwith/without GPDs, these intervalswere divided into 7med-
ication groups: tNSAID alone, COXIB alone, or pC2SI alone, tNSAID with hista-
mine-2 antagonist (H2RA), proton pump inhibitor (PPI), COXIB, or pC2SI. The Cox
regressions with covariates including age, gender, number of prior GI hospitaliza-
tion, co-medication, comorbidity were used to estimate the hazard ratios (HRs) of
drug switching among medication groups. RESULTS: There were 271,683 intervals
identified from97,834 patients. Given no prior GI history, patients in tNSIADH2RA
and tNSIADPPI were significantly less likely to switch (HR0.63, 95%CI0.61-
0.65); HR0.82, 95%CI0.72-0.93) than the tNSAID only. The HRs for drug switching
in COXIB, tNSIAD COXIB, pC2SI and tNSIADpC2SI, however, were 8.04, 6.64,
10.353 and 9.93 (all p value0.0001), respectively. CONCLUSIONS: Combination of
H2RA or PPI was shown less likely to switch than tNSAID alone. These results
suggest that H2RA or PPI could be an acceptable augmentation in clinical practice
for reducing potential GI adverse events.
PODIUM SESSION II:
CARDIOVASCULAR DISORDERS OUTCOMES STUDIES
CV1
STATIN PRESCRIPTION IN AUSTRALIA: A COMPARISON OF DIFFERENCES IN
PRESCRIBED DOSES AND POTENTIAL IMPACT ON HEALTH OUTCOMES
Ademi Z1, Liew D2
1University of Melbourne, Melbourne, Australia, 2University of Melbourne, Australia
OBJECTIVES: Statins, which vary considerably in their lipid-lowering potencies, are
prescribed at non-equivalent doses in Australia. This study sought to estimate the
effects of non-equivalent prescribing on low-density lipoprotein cholesterol
(LDL-C) levels and cardiovascular risk for the four most commonly prescribed
statins. METHODS: The weighted average daily doses (WADDs) of pravastatin,
simvastatin, atorvastatin and rosuvastatin prescribed in 2011, in Australia were
sourced from Pharmaceutical Benefit Scheme (PBS) data. Dose-specific, LDL-C
modifying potencies of these four statins were derived from the meta-analysis by
Law et al (BMJ 2003). The relationship between reduction in LDL-C achieved by
statin therapy and reduction in cardiovascular risk was derived from the recent
meta-regression by the Cholesterol Treatment Trialists’ Collaboration (Lancet
2010). This showed that for every 1mmol/L reduction in LDL-C, the relative risk for
a major cardiovascular (coronary and/or stroke) event was 0.78 (95%CI 0.76-0.80).
RESULTS: In 2011 the WADDs for pravastatin, simvastatin, atorvastatin and rosu-
vastatinwere 38.4mg, 36.3mg, 34.2mg and 14.9mg, respectively. The corresponding
expected reductions in LDL-C were 29.0%, 37.3%, 48.2% and 44.9%. Assuming a
pre-treatment LDL-C of 4.13mmol/L (the threshold for treatment recommended in
international guidelines), these lipid changes translated to expected reductions in
the risk of a major cardiovascular event of 26.3%, 33.9%, 43.8% and 40.0% for prav-
astatin, simvastatin, atorvastatin and rosuvastatin, respectively. CONCLUSIONS:
In Australia, atorvastatin and rosuvastatin are prescribed at higher LDL-C-reducing
doses than pravastatin and simvastatin, and hence would be more effective at
reducing cardiovascular risk. The advantages of atorvastatin and rosuvastatin will
be further enhanced when their acquisition prices fall in 2012.
A606 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 6 0 2 – A 6 8 1
